Sensipar is a brand name of cinacalcet, approved by the FDA in the following formulation(s):
SENSIPAR (cinacalcet hydrochloride - tablet; oral)
Manufacturer: AMGEN
Approval date: March 8, 2004
Strength(s): EQ 30MG BASE, EQ 60MG BASE, EQ 90MG BASE [RLD]
Has a generic version of Sensipar been approved?
No. There is currently no therapeutically equivalent version of Sensipar available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sensipar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Calcium receptor-active molecules
Patent 6,011,068
Issued: January 4, 2000
Inventor(s): Nemeth; Edward F. & Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Moe; Scott T.
Assignee(s): NPS Pharmaceuticals, Inc.
The Brigham and Women's Hospital
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Patent expiration dates:
- March 8, 2018
✓
Drug substance
✓
Drug product
Calcium receptor-active molecules
Patent 6,031,003
Issued: February 29, 2000
Inventor(s): Nemeth; Edward F. & Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Moe; Scott T.
Assignee(s): NPS Pharmaceuticals, Inc.
The Brigham and Women's Hospital
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Patent expiration dates:
Calcium receptor-active compounds
Patent 6,211,244
Issued: April 3, 2001
Inventor(s): Van Wagenen; Bradford C. & Moe; Scott T. & Balandrin; Manuel F. & DelMar; Eric G. & Nemeth; Edward F.
Assignee(s): NPS Pharmaceuticals, Inc.
The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. Preferably, the compound can mimic or block the effect of extracellular Ca.sup.2+ on a calcium receptor.
Patent expiration dates:
Calcium receptor-active molecules
Patent 6,313,146
Issued: November 6, 2001
Inventor(s): Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Nemeth; Edward F.
Assignee(s): NPS Pharmaceuticals, Inc.
The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
Patent expiration dates:
- December 14, 2016
✓
Drug substance
✓
Drug product
Rapid dissolution formulation of a calcium receptor-active compound
Patent 7,829,595
Issued: November 9, 2010
Inventor(s): Lawrence; Glen Gary & Alvarez; Francisco J. & Lin; Hung-Ren H. & Ju; Tzuchi R.
Assignee(s): Amgen Inc.
The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
Patent expiration dates:
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
See also...
- Sensipar Consumer Information (Drugs.com)
- Sensipar Consumer Information (Wolters Kluwer)
- Sensipar Consumer Information (Cerner Multum)
- Sensipar Advanced Consumer Information (Micromedex)
- Sensipar AHFS DI Monographs (ASHP)
- Cinacalcet Consumer Information (Wolters Kluwer)
- Cinacalcet Consumer Information (Cerner Multum)
- Cinacalcet Advanced Consumer Information (Micromedex)
- Cinacalcet AHFS DI Monographs (ASHP)
